We're back after a summer break! In this episode, Anthony and Bernie review the optimal approach to antimicrobial prophylaxis in hematology patients. How do you best choose prophylaxis for your patients? Where are we using data and where are we just making things up? Does everyone need antifungal, antibacterial, antiviral, and anti-PJP prophylaxis? We will demystify prophylaxis guidelines for you!
--------
49:40
--------
49:40
Episode 37: Spilling Drinks over Cytarabine Dosing
In this episode, Bernie and Anthony talk about some BIG changes in cytarabine dosing in AML consolidation after a recent practice changing article. Will this change your practice? Hunault, et al. NEJM. 2025.https://evidence.nejm.org/doi/full/10.1056/EVIDoa2400326
--------
58:36
--------
58:36
Episode 36: ODAC - Our Decisions Are Confusing
In this episode, Bernie and Anthony are joined by the Myeloma Man Dr. Manni Mohyuddin and lymphoma expert Dr. David Russler-Germain to discuss the very recent ODAC decisions on the STARGLO (glofitamab + GemOx) and AQUILA (daratumumab for smoldering multiple myeloma) trials. Did ODAC do their due diligence, or are there double standards? There is a lot to unpack in this episode!
--------
43:09
--------
43:09
CSO Encore Video Presentation - SWOG1826 & STARGLO Trials Critically Examined
This is a special encore video presentation of Anthony and Bernie teaming up with the Common Sense Oncology Journal Club series to discuss the SWOG1826 and STARGLO clinical trials. Tycel Phillips, MD, and Manju Sengar, MD join Anthony and Bernie for a great discussion of the trials and how they should impact practice! Join the Common Sense Oncology movement here! https://commonsenseoncology.org/
--------
1:10:35
--------
1:10:35
Dex and the Cytokine City: Managing CRS with Bispecifics
In this episode, Bernie and Anthony are joined by 3 hematology pharmacists - James Davis, PharmD, BCOP; Victoria Nachar, PharmD, BCOP; and Justine Preedit, PharmD, BCOP - to discuss the optimal management of CRS in patients receiving bispecific antibodies!Inspired by this recent paper:https://www.nature.com/articles/s41408-025-01222-y
Welcome to WolverHeme Happy Hour! This is a podcast dedicated to all things hematology! We discuss new data, debate controversial therapies, and talk about new and exciting research. While we nerd out about data, we'll have a few drinks!
Disclaimer: The views and opinions expressed on this podcast are solely those of the podcasters and guests and do not reflect the views or opinions of our employers or other affiliations.
Brasil